Foundation Fighting Blindness To Honor Xcovery Vision's Teri Ardleigh Swift At 'Banking on a Cure' Gala

Foundation Fighting Blindness To Honor Xcovery Vision’s Teri Ardleigh Swift At ‘Banking on a Cure’ Gala In Support Of Sight-Saving Research

New York, NY (February 4, 2013) The Foundation Fighting Blindness, a national nonprofit dedicated to sight-saving research, will honor Teri Ardleigh Swift, Xcovery Vision LLC’s Founder and VP of Business Development, with the organization’s Visionary Award at Banking on a Cure on Wednesday, March 6. The benefit, from 6-9 p.m. at the Plaza Hotel, will raise critical awareness and research funds toward preventions, treatments and cures for vision-robbing retinal degenerative diseases like age-related macular degeneration (AMD), retinitis pigmentosa (RP), Usher syndrome and related conditions.

“We’re thrilled to recognize Teri Ardleigh Swift’s visionary leadership in advancing research for age-related macular degeneration and other debilitating eye conditions through her work,” says Bill Schmidt, CEO, Foundation Fighting Blindness. “The funds raised through Banking on a Cure will help develop treatments in promising areas such as gene, stem cell and pharmaceutical therapies, with several clinical trials already underway for patients losing precious vision to retinal disease.”

An ophthalmology therapeutics company based in West Palm Beach, Florida, Xcovery Vision is conducting the first-ever clinical trial of an oral angiogenesis inhibitor for the treatment of neovascular wet AMD. This oral medication would be a less invasive treatment option for patients than the injection drugs currently on the market. Ms. Ardleigh Swift understands the impact of AMD because her late mother suffered from this leading cause of vision loss among older Americans. Formerly an alternate member of the U.S. Olympic Equestrian Team, she worked with BioCatalyst International and Upstate Biotechnology before becoming VP of Business Development for Xconomy LLC in 2006.

“I am humbled and touched by this honor from the Foundation Fighting Blindness. This is an organization I have admired for many years since my own mother was afflicted by macular degeneration. It was her suffering that inspired my interest and passion for this horrible condition that is affecting so many around the world. I look forward to working with the Foundation to continue to expand their outreach as their work is so important to coincide with the development of these drugs to fight all eye related afflictions," says Ardleigh Swift.

Banking on a Cure’s board chair is Daniel G. Bergstein, Paul Hastings senior counsel, who has three generations of family members affected with RP. The event’s honorary co-chairs are Foundation Fighting Blindness national trustees, Iris and Reuven Spiegel, who became involved because their daughter Tali is affected with RP. Mr. Spiegel, president and CEO of Israel Discount Bank, was honored with the Foundation’s Visionary Award in 2010. The event’s young professional co-chairs are Noah Rabinsky, Vice President of MidOcean Partners, and Bradford Manning, Partner at Macoma Capital Group.

Banking on a Cure will also feature a special performance by Justin Kauflin, a visually impaired jazz musician and songwriter who hasn’t let blindness interfere with his dream to pursue music.

What:

Banking on a Cure, Benefitting the Foundation Fighting Blindness

Where:

The Plaza Hotel
Fifth Avenue at 58th Street
New York, NY 10019

When:

Wednesday, March 6, 2013
6 p.m. Reception
7 p.m. Dinner & Award Presentation

About Foundation Fighting Blindness

The Foundation Fighting Blindness is a Columbia, Maryland-based non-profit organization driving the research that will lead to preventions, treatments and cures for retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases that affect more than 10 million Americans. Since 1971, the Foundation has raised over $500 million as the leading non-governmental funder of retinal research. Breakthrough Foundation-funded studies using gene therapy have restored significant vision in children and young adults who were previously blind, paving the way for additional clinical trials to treat a variety of retinal degenerative diseases, and proving a cure is in sight. With a network of nearly 50 chapters, the Foundation also provides support, information and resources to affected individuals and their families in communities across the country.

Original Date: 
Monday, February 4, 2013